INMB Inmune Bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INMB

Price (delayed)

$11.57

Market cap

$208.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.67

Enterprise value

$183.16M

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The ...

Highlights
The debt has declined by 32% year-on-year and by 19% since the previous quarter
The revenue has dropped by 59% year-on-year and by 31% since the previous quarter
The gross profit has shrunk by 59% YoY and by 31% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inmunebio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of INMB
Market
Shares outstanding
18.03M
Market cap
$208.57M
Enterprise value
$183.16M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.58
Price to sales (P/S)
1,342.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,181.65
Earnings
Revenue
$155,000
EBIT
-$30.01M
EBITDA
-$30.01M
Free cash flow
-$11.98M
Per share
EPS
-$1.67
Free cash flow per share
-$0.67
Book value per share
$2.07
Revenue per share
$0.01
TBVPS
$2.25
Balance sheet
Total assets
$57M
Total liabilities
$18.86M
Debt
$10.44M
Equity
$37.34M
Working capital
$21.48M
Liquidity
Debt to equity
0.28
Current ratio
2.16
Quick ratio
1.94
Net debt/EBITDA
0.85
Margins
EBITDA margin
-19,360%
Gross margin
100%
Net margin
-19,360%
Operating margin
-19,360%
Efficiency
Return on assets
-45.6%
Return on equity
-64.1%
Return on invested capital
-638.6%
Return on capital employed
-77.9%
Return on sales
-19,360%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INMB stock price

How has the Inmune Bio stock price performed over time
Intraday
3.95%
1 week
2.48%
1 month
14.55%
1 year
59.59%
YTD
2.75%
QTD
-1.53%

Financial performance

How have Inmune Bio's revenue and profit performed over time
Revenue
$155,000
Gross profit
$155,000
Operating income
-$30.01M
Net income
-$30.01M
Gross margin
100%
Net margin
-19,360%
The operating margin has shrunk by 165% YoY and by 53% QoQ
The net margin has dropped by 165% year-on-year and by 58% since the previous quarter
The revenue has dropped by 59% year-on-year and by 31% since the previous quarter
The gross profit has shrunk by 59% YoY and by 31% QoQ

Growth

What is Inmune Bio's growth rate over time

Valuation

What is Inmune Bio stock price valuation
P/E
N/A
P/B
5.58
P/S
1,342.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,181.65
The EPS has declined by 10% since the previous quarter and by 10% year-on-year
The P/B is 80% higher than the 5-year quarterly average of 3.1 and 64% higher than the last 4 quarters average of 3.4
INMB's equity is down by 38% year-on-year and by 15% since the previous quarter
The price to sales (P/S) is 85% higher than the last 4 quarters average of 725.0
The revenue has dropped by 59% year-on-year and by 31% since the previous quarter

Efficiency

How efficient is Inmune Bio business performance
The ROS has dropped by 165% year-on-year and by 58% since the previous quarter
The ROIC has plunged by 131% from the previous quarter
Inmune Bio's ROE has plunged by 58% YoY and by 23% from the previous quarter
INMB's ROA is down by 45% YoY and by 20% QoQ

Dividends

What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INMB.

Financial health

How did Inmune Bio financials performed over time
The current ratio has dropped by 64% year-on-year and by 32% since the previous quarter
INMB's quick ratio has shrunk by 59% YoY and by 33% QoQ
The debt is 72% smaller than the equity
INMB's equity is down by 38% year-on-year and by 15% since the previous quarter
The debt has declined by 32% year-on-year and by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.